**Purpose:** Bone tissue engineering remains hampered by inadequate scaffold design and regulatory limitations on autologous cell use. We developed a novel system to silence and reactivate TGF-ß activating kinase 1 (TAK1), which mediates TGF-β1 and BMP2. We hypothesize that *Tak1* can be initially silenced to increase local cell proliferation followed by *Tak1* reactivation to stimulate bone differentiation, providing scaffold and cell-free bone healing.

**Methods:** We developed a novel dual-recombinase system (Cre/lox; FLP/FRT) to allow silencing and reactivation of *Tak1*. Critical sized-calvarial defects were performed and mice received: 1. Ad.LacZ (control) 2. Ad.Cre (knockout) or 3. Ten days Ad.Cre (knockout) followed by Ad.FLP (reactivation) to modulate *Tak1* expression. Cellular proliferation and differentiation were quantified histologically. MicroCT was used to quantify bone healing. *In vitro* studies with calvarial osteoblasts confirmed these findings.

**Results:** Loss of *Tak1* with Ad.Cre increased cellular proliferation (Ki67 immunostaining; Fig. 1A) while suppressing osteogenesis (Osterix immunostaining) within the defect. Ad.Cre followed by Ad.FLP stimulated increased cell proliferation followed by enhanced osteogenic differentiation. Timed *Tak1* suppression followed by *Tak1* activation improved bone healing compared to controls by microCT quantification. *In vitro* results (Fig. 1B, 1C) with calvarial osteoblasts were consistent with *in vivo* findings.

**Conclusion:** These results validate that TAK1 can be mediated therapeutically to first potentiate cellular proliferation and then stimulate osteogenic differentiation to maximize bone healing without introducing exogenous scaffolds or cells.
